PainChek's Annual Recurring Revenue Grows to AU$4 Million as of January-End

MT Newswires Live
Jan 30

PainChek (ASX:PCK) said its annual recurring revenue grew to AU$4 million at the end of January with the implementation of licenses, and it anticipates an annual recurring revenue of AU$5.6 million after all licenses have been implemented, according to a Friday Australian bourse filing.

The company also has a pipeline for about AU$1.9 million in annual recurring revenue under negotiation across US, Canada, UK, and Australia-New Zealand, the filing said.

The company plans to continue negotiating with the Centers for Medicare & Medicaid Services in the US for an additional specific PainChek Current Procedural Terminology reimbursement code by April, per the filing.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10